 I. For patients treated in the expansion phase of this study: a to assess copper transport protein CTR1 score; b to assess changes in global DNA methylation; and c to measure changes in oxaliplatin levels in tumor biopsies between pretreatment and day 12 of the first cycle of 5-azacytidine plus oxaliplatin therapy. 